Department of Surgery, Division of Surgical Oncology, University of Arizona, 1501 N. Campbell Avenue, Room 4327, P.O. Box 245131, Tucson, Arizona 85724, USA.
Oncologist. 2012;17(3):405-18. doi: 10.1634/theoncologist.2011-0282. Epub 2012 Feb 14.
Radiation-induced sarcoma (RIS) is a rare, aggressive malignancy. Breast cancer survivors treated with radiotherapy constitute a large fraction of RIS patients. To evaluate evidenced-based practices for RIS treatment, we performed a systematic review of the published English-language literature.
We performed a systematic keyword search of PubMed for original research articles pertaining to RIS of the breast. We classified and evaluated the articles based on hierarchical levels of scientific evidence.
We identified 124 original articles available for analysis, which included 1,831 patients. No randomized controlled trials involving RIS patients were found. We present the best available evidence for the etiology, comparative biology to primary sarcoma, prognostic factors, and treatment options for RIS of the breast.
Although the evidence to guide clinical practice is limited to single institutional cohort studies, registry studies, case-control studies, and case reports, we applied the available evidence to address clinically relevant questions related to best practice in patient management. Surgery with widely negative margins remains the primary treatment of RIS. Unfortunately, the role of adjuvant and neoadjuvant chemotherapy remains uncertain. This systematic review highlights the need for additional well-designed studies to inform the management of RIS.
放射性诱导肉瘤(RIS)是一种罕见且侵袭性的恶性肿瘤。接受放射治疗的乳腺癌幸存者是 RIS 患者的主要群体。为了评估 RIS 治疗的循证实践,我们对已发表的英文文献进行了系统综述。
我们在 PubMed 上进行了系统的关键词搜索,以查找与乳房 RIS 相关的原始研究文章。我们根据科学证据的层次结构对文章进行分类和评估。
我们确定了 124 篇可供分析的原始文章,其中包括 1831 名患者。未发现涉及 RIS 患者的随机对照试验。我们介绍了 RIS 乳房的病因、与原发性肉瘤的比较生物学、预后因素以及治疗选择的最佳现有证据。
尽管指导临床实践的证据仅限于单机构队列研究、登记研究、病例对照研究和病例报告,但我们应用现有证据解决了与患者管理最佳实践相关的临床相关问题。广泛切缘的手术仍然是 RIS 的主要治疗方法。不幸的是,辅助和新辅助化疗的作用仍不确定。本系统综述强调需要进行更多精心设计的研究,以为 RIS 的管理提供信息。